Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Repository Usage Stats
Maximum Tolerated Dose
Aged, 80 and over
Leukemia, Myeloid, Acute
Published Version (Please cite this version)10.1038/bcj.2017.1
Publication InfoErba, Harry; Swords, RT; Watts, J; Altman, JK; Maris, M; Anwer, F; ... DeAngelo, DJ (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood cancer journal, 7(2). pp. e520. 10.1038/bcj.2017.1. Retrieved from https://hdl.handle.net/10161/19549.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Instructor in the Department of Medicine
I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia v